REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 78 filers reported holding REPLIMUNE GROUP INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $149,346 | -65.4% | 17,716 | -4.8% | 0.00% | -100.0% |
| Q2 2023 | $432,055 | -66.2% | 18,607 | -74.3% | 0.00% | -80.0% |
| Q1 2023 | $1,277,048 | -39.0% | 72,313 | -6.0% | 0.01% | -37.5% |
| Q4 2022 | $2,093,312 | +281.3% | 76,960 | +144.8% | 0.01% | +166.7% |
| Q2 2022 | $549,000 | -25.0% | 31,434 | -27.1% | 0.00% | 0.0% |
| Q1 2022 | $732,000 | -50.4% | 43,110 | +12.2% | 0.00% | -50.0% |
| Q2 2021 | $1,476,000 | +36.4% | 38,421 | +8.4% | 0.01% | 0.0% |
| Q1 2021 | $1,082,000 | -59.8% | 35,452 | -49.7% | 0.01% | -70.0% |
| Q4 2020 | $2,690,000 | +277.8% | 70,522 | +128.0% | 0.02% | +100.0% |
| Q3 2020 | $712,000 | +22.5% | 30,931 | +32.4% | 0.01% | +11.1% |
| Q2 2020 | $581,000 | +5.6% | 23,363 | -57.6% | 0.01% | -35.7% |
| Q1 2020 | $550,000 | -56.7% | 55,125 | -37.8% | 0.01% | +75.0% |
| Q4 2019 | $1,271,000 | +319.5% | 88,583 | +306.4% | 0.01% | +166.7% |
| Q3 2019 | $303,000 | +27.8% | 21,799 | +34.6% | 0.00% | +50.0% |
| Q2 2019 | $237,000 | – | 16,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 4,763,380 | $129,088,000 | 18.25% |
| Atlas Venture Life Science Advisors, LLC | 3,209,627 | $86,981,000 | 7.99% |
| Redmile Group, LLC | 3,866,512 | $104,782,000 | 2.38% |
| FRAZIER MANAGEMENT LLC | 650,862 | $17,638,000 | 1.36% |
| Mesirow Financial Investment Management, Inc. | 15,326 | $415,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,075,464 | $29,145,000 | 1.03% |
| EMERALD ADVISERS, LLC | 989,958 | $26,828,000 | 0.99% |
| BVF INC/IL | 926,529 | $25,109,000 | 0.91% |
| Integral Health Asset Management, LLC | 100,000 | $2,710,000 | 0.75% |
| Artal Group S.A. | 900,000 | $24,390,000 | 0.66% |